Paralysis was maintained in sheep by computer-controlled infusion of atracurium, using the integrated electromyogram as a measure of neuromuscular transmission. A number of experiments were conducted to ascertain the average infusion rate required to achieve a given level of paralysis for one hour. Each experiment yielded a point on a plot of paralysis versus infusion rate. A dose-response curve based upon a simple model of drug receptor interaction at the neuromuscular junction was fitted to the experimental points by least squares and is able to provide a useful explanation of clinically observed behaviour. The recovery time was also measured in each experiment and plotted against both prior level of paralysis and prior average infusion rate.
METHOD
Three adult merino sheep weighing 50, 50 and 40 kg were used. A minimum time (two weeks) was allowed between successive studies on each sheep. Anaesthesia was induced with thiopentone sodium, the usual dose being 12 mg/kg and maintained with 60070 N 2 0/40070 02 supplemented by a thiopentone sodium infusion. The animals were intubated after thiopentone induction and ventilated to an end tidal CO 2 of 5070. The sheep's temperature was monitored and the studies performed in a constant temperature room.
The EMG was recorded by surface electrodes (gold-plated small crocodile clips) applied to the subcostal area of the abdomen with a smear of Redux Creme (Hewlett Packard 651-1021) over the upper rectus abdominis muscle. The 7th intercostal nerve was supramaximally stimulated in the intercostal space by a coaxial needle at a rate of 0.1 Hz with a pulse width of 0.1 msec. The rectified EMG response of each stimulus was integrated over an interval of 10 msec and displayed as a percentage of the value obtained before the muscle relaxant infusion was started.
In an initial experiment bolus doses of atracurium were given to assess the effective dose needed to depress the IEMG by about 60070.
In the computer-controlled experiments a bolus dose of atracurium was given to depress the IEMG to about the desired level and then an infusion of drug diluted to 2 mg/ml in isotonic saline started, the rate being controlled by computer. An isotonic saline infusion was placed in the right external jugular vein, and the drug solution added close to the intravenous end of the infusion cannula to avoid delay in reaching the blood stream. The thiopentone and atracurium infusions were placed in opposite veins to minimise the risk of alkaline hydrolysis of the atracurium. The atracurium was kept at 4°C until dilution with isotonic saline at 20°C and the ambient temperature remained constant at 20 °C throughout each study so that the diluted solution of the drug was kept under similar conditions throughout all the studies.
The technique of computer-control was unchanged from that used with the longeracting drugs. 3 The IEMG was measured and compared with the desired level and the infusion syringe switched on for a fraction of each minute, the on-time being adjusted by the computer to deliver the dose needed to produce the desired level of paralysis.
In all experiments the IEMG was kept under computer-control for a ninety-minute period. The infusion was then discontinued and the IEMG allowed to recover spontaneously. Neostigmine was not used as one goal of the experiments was to determine the duration of At the completion of each experiment the dose rate in /1g/kg/minute was calculated for each of the six ten-minute periods of the thirtyto ninety-minute period and compared with the average dose rate over the same sixty minutes to find whether any trend was discernible. Figure 1 shows the time course of IEMG for the initial experiment, in which two bolus doses of atracurium of 100 /1g/kg were given 33 minutes apart. Figure 2 shows the IEMG and infusion rate for the duration of a typical computercontrolled experiment. Sixteen experiments were carried out, one at 10070 paralysis and three each at five more profound levels of paralysis.
RESULTS
Calculations of infusion rates were based on recordings in the thirty-to ninety-minute period of each experiment because the IEMG control was steady by the end of 30 minutes, and remained so for a further hour. It was noted that the rate of infusion in each ten-minute segment of the sixty-minute period differed from the average over sixty minutes in most cases by less than 5%. An occasional larger variation was noted, but no steady trend was found. Figure 3 shows the dose response results for the sixteen experiments. The horizontal axis shows the average infusion rate over the sixty minutes of steady IEMG for each experiment, and the vertical axis shows percentage paralysis as the 'response' to the drug. Paralysis is simply . .. An expression of the form given below was then fitted to the experimental points by the method of least squares and is shown as the solid line in Figure 3 .
where P is paralysis, expressed as a percentage, d is dose rate in /ig/kg/min and Po, do, c and df are constants (see Discussion). Here P o =1090J0, d o =2.1 /ig/kg/min, c=1.5 /ig/kg/min and df = 15.1 /ig/kg/min. No attempt has been made to quantify the adequacy of fit because of the small number of experiments involved and the spread of the results. Figure 4 shows the recovery time t.95, the time required for recovery from 'turn-off' to 95070 of the pre-paralysis level of IEMG, plotted against the level of paralysis prior to recovery. the responses are identical, indicating that the drug is non-cumulative in the sheep, in keeping with published results in man and other species. 5 ,6 These doses and the recovery times compare closely with those needed to produce similar levels of paralysis in children. 7 With regard to the computer-controlled studies, the first point to note is that no progressive decrease in infusion rate for steady IEMG in the thirty-to ninety-minute period was evident. This further confirms published evidence that atracurium is a non-cumulative drug. 6 Turning to the question of the relationship between paralysis and average dose rate, there is justification for seeking to fit an equation of the form shown to the experimental points ( Figure 3) . The equation is derived from a model proposed by Lam and Lampard 8 for the case of an antagonist to acetylcholine which acts purely by competition at the neuromuscular junction.
In the equation, Po is a constant (greater than 100) which depends on the mean fractional occupancies of receptors by acetylcholine to achieve zero and 100070 response respectively; do is the dose rate of antagonist for threshold paralysis; c is a constant depending on do, on the concentration of ACh at the receptors during a twitch and on the equilibrium constants for binding of both ACh and antagonist; df is the dose rate needed to just cause 100% paralysis.
From the form of the theoretical curve it can be seen that a threshold dose is necessary to produce measurable paralysis and then large increases in paralysis occur with small increases in dose rate. As the degree of paralysis increases the curve reaches a plateau and the relationship reverses: a large increase in dose rate produces a small change in paralysis. This relationship is of fundamental importance in the clinical use of nondepolarising neuromuscular blockers where increments of dosage at deeper levels of paralysis produce minimal measurable change, but during recovery the reverse relationship is observed.
The plateau reached by the curve in Figure 3 may also explain the reported variability of dosage of nondepolarising blockers. 9 When these drugs are given during profound levels of paralysis, there may be little change in the depth of paralysis irrespective of the size of the dose. The total dose used would then also be quite variable, and not reliable as a basis for comparing drugs. Hence the technique of determining dose rates at steady levels gives a more accurate result, and also enables different drugs to be compared more precisely.
With regard to recovery, the t95 measure has been used to enable a comparison with other published results. 7 Furthermore, this measure is considered to be appropriate for clinical use, where the anaesthetist is most likely to want to know how long recovery will take from the time the infusion is terminated.
From Figures 4 and 5 it is clear that the recovery time is well related to prior dose rate ( Figure 5 ) but less well related to prior level of paralysis (Figure 4 ). Figure 5 is therefore likely to be of greater use in clinical practice.
No attempt has been made to fit curves to the data in Figures 4 or 5 , since a theoretical basis for relationships has not yet been worked out. Nevertheless the data should provide a helpful guide as it stands.
Neostigmine may be necessary if inadvertently deep paralysis has been produced late in the anaesthetic, but there is no risk of recurrence of paralysis because the elimination of atracurium (t ' Iz{3 = 20 minutes I~ is shorter than the standard non depolarising blocker, tubocurarine, (t ' I2{3 = 171.5 minutes 11 and neostigmine (t'l2{3 = 77 minutesl~.
Atracurium has already been widely reported as a clinically useful drug both by conventional repeated bolus doses 13 and by infusion based on empirical data. 14 These studies confirm this view, but they also show it is particularly well suited to infusion under computer control.
